Leadership

Bill Zeping Xu, CEO & Co-Founder

13-year professional experience across Medical & Pharmaceutical R&D, Advertising, and STM publishing
Over 9 years of experience leading cross functional teams and driving strong operating performance
Founder, Beijing High-Med Sci and Tech Consulting Co.,Ltd. and Fuze International Hospital Management (Beijing) Co., Ltd.
EMBA, University of Toronto
Master’s degree in Pharmaceutical Analysis, University of Strathclyde, UK
Bachelor’s degree in Pharmacy, China Pharmaceutical University, China PR

Michael Wu, CMO & Co-Founder

17+ years medical experiences in pharmaceutical companies including Clinical Development and Medical Affairs
Pfizer China Inflammation and Immunology Medical Lead, accelerated tofacitinib launch and pipeline products into China, helped China I&I achieve best-in-class capabilities, deliver high-quality clinical programs
Set up collaboration with China Rheumatology Association to generate real world data and increase Rheumatoid Arthritis (RA) treatments standard. Global committee member of publication sub-committee, and grant review committee
8 years in Clinical Development in areas including cardiovascular, oncology and immunology as CRA, clinical study operation lead and clinical scientist
Led Tocilizumab (Actemra) registration study in China
MD degree in Clinical Medicine, Shanghai Jiaotong University
Practiced as Neurosurgeon in Shanghai 6th People’s hospital.

Finance

Mr. Yu Lou

Ex-VP of Novartis Investment, China. Over 20-year government affair experience with CFDA/MoH/Pricing Bureau of National Development and Reform Commission. Valuable pricing strategy of products.

Mr. Jianjun Wang

Financial director, investor, ex director of China Import & Export Bank (Africa branch). 13-years financial service, strategy and mortgage experience for nation-owned projects.

Mr. Jian Zhang

MBA, Director of M&A, Over 12 years M&A in pharmaceutical, medical and hospital. Outstanding track record over USD 1B.

Technical

Dr. Ping Li

Over 20-year registry affair with responsible for IND/NDA application and response of queries for Aripiprazole, Rebamipide, Tolvaptan, etc.

Dr. Huihui Miao

M.D., Clinical Anaesthesiologist, researcher, post-doc in Harvard Medical School and University of Toronto. 12-year focus on mechanism of pain, neuroscience and anaesthetic device technology.

Dr. Bing Hao

M.D., ex-CEO of CRO, 5-year clinical practice and 16-year clinical strategy, operation, portfolio of pipeline. 90% of Japanese pharma was his clients.

Advisor

Prof. Aiping Zhou

M.D., Chief Oncologist, PI, Editor and peer reviewer of National Oncology Guideline. Deputy Director of Department of Internal Medicine, Cancer Hospital, Chinese Academy of Medical Sciences

Prof. Huayong Zhang

M.D., Deputy Director of Department of Rheumatology, Drum Tower Hospital, Nanjing

Prof. Janzhong Shou

M.D., Chief Oncologist, Acting Editor of leading journals. Deputy Director of Department of Urine Surgery, Cancer Hospital, Chinese Academy of Medical Sciences